PROTAC Technology: Opportunities and Challenges-Reference-Cited by-同舟云学术

PROTAC Technology: Opportunities and Challenges

Published:2020-03-12 Issue:3 Volume:11 Page:237-240
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Gao Hongying¹²^ORCID,Sun Xiuyun¹²^ORCID,Rao Yu¹^ORCID

Affiliation:

1. MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing 100084, P.R. China

2. Tsinghua University-Peking University Joint Center for Life Sciences, Beijing 100084, P.R. China

Funder

Ministry of Science and Technology of the People's Republic of China

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.9b00597

Reference23 articles.

1. Structural basis of PROTAC cooperative recognition for selective protein degradation

2. Catalytic in vivo protein knockdown by small-molecule PROTACs

3. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6

4. Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach

5. Delineating the role of cooperativity in the design of potent PROTACs for BTK

Cited by 210 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a proteolysis targeting chimera (PROTAC) as a potent regulator of FOXP3;Bioorganic & Medicinal Chemistry Letters;2024-11

2. FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives;European Journal of Medicinal Chemistry;2024-11

3. The synthesis of 1,2,3-triazoles as binders of D-dopachrome tautomerase (D-DT) for the development of dual-targeting inhibitors;European Journal of Medicinal Chemistry;2024-10

4. Development and validation of LC-MS/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide (ARV-110) and vepdegestrant (ARV-471);Journal of Pharmaceutical and Biomedical Analysis;2024-10

5. PROTAC-mediated conditional degradation of the WRN helicase as a potential strategy for selective killing of cancer cells with microsatellite instability;Scientific Reports;2024-09-06